Ironwood Pharmaceuticals
Discovered linaclotide (Linzess) and shares US profits on it with AbbVie.
Share price
$3.82
Up 142% over 12 monthsWhat analysts expect
Buy
Buy45%
Hold55%
Sell0%
Price target for the next 12 months
$6.23Up 75% compared with the current price
Price now $3.56Average targetLowest $3.70 to highest $10.00
7 analysts. 4 of the 7 analysts rate it Hold. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $389M
- Yearly profit
- $130M
- Company value
- $631M
Revenue and profit for the last twelve months reported.
Peptides in this book
- LinaclotidePrescription
Recent news
- 2026-08-06 Ironwood raises 2026 guidance after strong second quarter Linzess results Business Wire
Prices are delayed and figures rounded. Not investment advice.